Table SI. Baseline demographics of patients enrolled in the pooled FIXTURE and ERASURE studies who completed the Psoriasis Symptom Diary at baseline ($n = 820$)

Characteristics	Secukinumab 150 mg ($n = 229$)	Secukinumab 300 mg ($n = 226$)	Etanercept 50 mg ($n = 137$)	Placebo ($n = 228$)
Age, mean ± SD, years	45.7±12.9	43.3±13.4	43.7±13.1	43.1±11.7
Male, *n* (%)	151 (65.9)	142 (62.8)	98 (71.5)	163 (71.5)
White, *n* (%)	190 (83.0)	189 (83.6)	107 (78.1)	185 (81.1)
Body weight, kg, mean±SD	89.3±22.2	90.2±23.1	87.8±21.7	89.4±23.2
Body mass index, kg/m^2, mean±SD	29.8±6.8	30.4±7.4[a]	29.4±6.5	29.7±7.3
PASI (0–72), mean±SD (range)	21.8±9.0 (12.0–69.6)	21.9±9.0 (12.0–64.2)	21.3±8.0 (12.0–49.6)	21.7±8.9[b] (10.6–55.5)
Body surface area, %, mean±SD	31.2±18.0	29.2±17.6	29.7±16.9	29.0±15.6
Investigator's Global Assessment (0–4) category, *n* (%)				
Moderate (IGA = 3)	152 (66.4)	143 (63.3)	87 (63.5)	139 (61.0)
Severe (IGA = 4)	77 (33.6)	83 (36.7)	50 (36.5)	89 (39.0)
Psoriasis Symptom Diary scores (0–10)[c], mean±SD				
Itching severity	6.46±2.37	6.42±2.39	6.18±2.43	6.06±2.45
Pain severity	5.29±3.06	5.49±2.99	5.28±2.96	4.97±3.03
Scaling severity	6.47±2.41	6.40±2.55	6.33±2.61	6.18±2.44

[a]$n = 225$. [b]$n = 227$. [c]A score of 0 = no itching/pain/scaling; 10 = itching/pain/scaling as bad as you can imagine.
SD: standard deviation; PASI: Psoriasis Area and Severity Index.